Resource Summary Report

Generated by dkNET on Apr 22, 2025

Alzheimer's Research Forum

RRID:SCR_006416
Type: Tool

Proper Citation

Alzheimer's Research Forum (RRID:SCR_006416)

Resource Information

URL: http://www.alzforum.org/

Proper Citation: Alzheimer's Research Forum (RRID:SCR_006416)

Description: A community building portal dedicated to understanding Alzheimer's disease and related disorders, it reports on the latest scientific findings from basic research to clinical trials, creates and maintains public databases of essential research data and reagents, and produces discussion forums to promote debate, speed the dissemination of new ideas, and break down barriers across disciplines.

Abbreviations: ALZForum, ARF

Resource Type: community building portal, discussion, portal, data or information resource, topical portal, narrative resource, disease-related portal

Keywords: alzheimer's disease, human, mouse, community building portal, forum, FASEB list

Related Condition: Alzheimer's disease

Funding: grants ;
individual donations

Availability: Free, Acknowledgement requested

Resource Name: Alzheimer's Research Forum

Resource ID: SCR_006416

Alternate IDs: nif-0000-00095

License URLs: http://www.alzforum.org/terms-of-use

Record Creation Time: 20220129T080236+0000

Record Last Update: 20250422T055314+0000

Ratings and Alerts

No rating or validation information has been found for Alzheimer's Research Forum.

No alerts have been found for Alzheimer's Research Forum.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 106 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET.

Hao M, et al. (2025) Nanomaterials-mediated lysosomal regulation: a robust protein-clearance approach for the treatment of Alzheimer's disease. Neural regeneration research, 20(2), 424.

Chen J, et al. (2024) Amyloid Precursor Protein: A Regulatory Hub in Alzheimer's Disease. Aging and disease, 15(1), 201.

Singh H, et al. (2024) New insights into the therapeutic approaches for the treatment of tauopathies. Neural regeneration research, 19(5), 1020.

Batista AF, et al. (2024) The Importance of Complement-Mediated Immune Signaling in Alzheimer's Disease Pathogenesis. International journal of molecular sciences, 25(2).

Area-Gomez E, et al. (2024) Towards a Unitary Hypothesis of Alzheimer's Disease Pathogenesis. Journal of Alzheimer's disease : JAD, 98(4), 1243.

de Boni L, et al. (2024) Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson's patients. EMBO molecular medicine, 16(7), 1657.

Gilani N, et al. (2024) Homozygous TREM2 c.549del; p.(Leu184Serfs*5) variant causing Nasu-Hakola disease in three siblings in a consanguineous Iraqi family: Case report and review of literature. Molecular genetics & genomic medicine, 12(6), e2476.

Rizzi L, et al. (2024) Exploring the significance of caspase-cleaved tau in tauopathies and as a complementary pathology to phospho-tau in Alzheimer's disease: implications for biomarker development and therapeutic targeting. Acta neuropathologica communications, 12(1), 36.

Chu D, et al. (2024) Tau truncation in the pathogenesis of Alzheimer's disease: a narrative review. Neural regeneration research, 19(6), 1221.

Stellick Bedrejo CA, et al. (2024) Do beta-amyloid-targeted interventions improve cognition, physical functioning, and overt behaviour of Alzheimer's Disease (AD) patients: Protocol for meta-analysis of Phase 3 clinical trials both completed and terminated. PloS one, 19(9), e0307761.

Chu J, et al. (2024) Biomaterials-based anti-inflammatory treatment strategies for Alzheimer's disease. Neural regeneration research, 19(1), 100.

Zhang Y, et al. (2024) E674Q (Shanghai APP mutant), a novel amyloid precursor protein mutation, in familial late-onset Alzheimer's disease. Genes & diseases, 11(2), 1022.

Arber C, et al. (2024) The presenilin 1 mutation P436S causes familial Alzheimer's disease with elevated A?43 and atypical clinical manifestations. Alzheimer's & dementia : the journal of the Alzheimer's Association, 20(7), 4717.

Cummings J, et al. (2023) Lecanemab: Appropriate Use Recommendations. The journal of prevention of Alzheimer's disease, 10(3), 362.

Yu HJ, et al. (2023) Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study. EBioMedicine, 94, 104665.

Hata S, et al. (2023) Brain p3-Alc? peptide restores neuronal viability impaired by Alzheimer's amyloid ?-peptide. EMBO molecular medicine, 15(5), e17052.

Zhang Y, et al. (2023) Amyloid ?-based therapy for Alzheimer's disease: challenges, successes and future. Signal transduction and targeted therapy, 8(1), 248.

Visconte C, et al. (2023) Plasma microglial-derived extracellular vesicles are increased in frail patients with Mild Cognitive Impairment and exert a neurotoxic effect. GeroScience, 45(3), 1557.

Quan M, et al. (2023) Shared and unique effects of ApoE?4 and pathogenic gene mutation on cognition and imaging in preclinical familial Alzheimer's disease. Alzheimer's research & therapy, 15(1), 40.

Zhang B, et al. (2023) Design of the formalized and integrated Alzheimer's Disease Ontology

and its application in retrieving textual data via text mining. Database : the journal of biological databases and curation, 2023.